Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label weekly Alpha-1 MP safety study in Japanese patients with alpha1 antitrypsin deficiency
jRCT2080225207Completed
- Sponsor
- Grifols
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Grifols. Primary endpoint: Primary safety and tolerability of long-term weekly Alpha-1 MP. Started May 2020; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on jRCT2080225207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225207.